Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease

Patients with sickle cell disease (SCD) are at risk for bone fragility from multiple factors including vitamin D deficiency. To date, no studies have evaluated the efficacy and safety of long-term vitamin D therapy for bone disease in children with SCD. We report a cohort of 4 children with SCD foun...

Full description

Saved in:
Bibliographic Details
Published inJournal of pediatric hematology/oncology Vol. 40; no. 6; p. 458
Main Authors Williams, Kristen M, Lee, Margaret T, Licursi, Maureen, Brittenham, Gary M, Fennoy, Ilene
Format Journal Article
LanguageEnglish
Published United States 01.08.2018
Subjects
Adolescent
Anemia, Sickle Cell - complications
Anemia, Sickle Cell - drug therapy
Bone Density - drug effects
Bone Diseases - drug therapy
Bone Diseases - etiology
Child
Cholecalciferol - administration & dosage
Female
Humans
Male
Time Factors
Vitamin D Deficiency - drug therapy
Vitamin D Deficiency - etiology
Online AccessGet more information

Cover

More Information
Summary:Patients with sickle cell disease (SCD) are at risk for bone fragility from multiple factors including vitamin D deficiency. To date, no studies have evaluated the efficacy and safety of long-term vitamin D therapy for bone disease in children with SCD. We report a cohort of 4 children with SCD found to have severe vitamin D deficiency, secondary hyperparathyroidism, and abnormal bone mineral density treated with monthly high-dose oral cholecalciferol over 2 years. All patients exhibited a positive response to therapy without hypervitaminosis D or hypercalcemia. Further studies are needed to standardize guidelines for optimal vitamin D dosing and prevention of toxicity.
ISSN:1536-3678
DOI:10.1097/MPH.0000000000001155